Summary


The majority of meningiomas, the most common primary brain tumor, are considered to be benign, and characteristic magnetic resonance imaging features allow a preliminary diagnosis. Although approximately 80% of these tumors are slow growing, some subtypes are associated with a less favorable outcome and a higher recurrence rate. Previous histopathological grading systems did not consistently predict their natural history, with The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), histomorphological features and genetic/molecular profiles have now become more evident for a comprehensive diagnosis and in understanding of recurrence risk to better guide the choice of optimal treatment. We hereby discuss the latest updates in the management of intracranial meningioma